ValuEngine upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a report published on Thursday, ValuEngine reports.
A number of other brokerages have also commented on NTLA. Roth Capital initiated coverage on shares of Intellia Therapeutics in a research note on Monday, June 10th. They issued a neutral rating and a $16.00 price target for the company. Evercore ISI started coverage on shares of Intellia Therapeutics in a research report on Thursday, April 11th. They set an outperform rating for the company. Chardan Capital restated a buy rating and set a $57.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, May 28th. Zacks Investment Research lowered shares of Intellia Therapeutics from a buy rating to a hold rating in a research report on Wednesday, July 10th. Finally, Wedbush upgraded shares of Intellia Therapeutics from a neutral rating to an outperform rating and boosted their target price for the company from $20.00 to $21.00 in a research report on Friday, May 3rd. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $25.31.
NTLA stock traded down $0.77 during mid-day trading on Thursday, reaching $16.84. 42,050 shares of the stock traded hands, compared to its average volume of 534,196. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.74 and a quick ratio of 7.74. Intellia Therapeutics has a one year low of $11.03 and a one year high of $32.95. The firm has a market cap of $795.81 million, a PE ratio of -8.51 and a beta of 2.62. The company has a 50-day simple moving average of $16.29.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.05. The firm had revenue of $11.10 million for the quarter, compared to analyst estimates of $7.15 million. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.29%. The business’s quarterly revenue was up 44.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.52) earnings per share. As a group, equities analysts anticipate that Intellia Therapeutics will post -2.41 earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Advisers LP bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $288,000. Dimensional Fund Advisors LP grew its position in shares of Intellia Therapeutics by 502.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 260,259 shares of the company’s stock valued at $3,552,000 after acquiring an additional 217,071 shares during the period. Geode Capital Management LLC lifted its stake in shares of Intellia Therapeutics by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 359,479 shares of the company’s stock valued at $4,906,000 after buying an additional 17,771 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Intellia Therapeutics by 11.9% during the 1st quarter. Rhumbline Advisers now owns 53,847 shares of the company’s stock valued at $920,000 after buying an additional 5,716 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in Intellia Therapeutics by 942.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,648 shares of the company’s stock worth $131,000 after purchasing an additional 6,914 shares in the last quarter. Institutional investors own 85.95% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Read More: Range Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.